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Abstract
Rift Valley fever virus (RVFV) (genus Phlebovirus, family Bunyaviridae) is a negative-stranded RNA virus with a tripartite
genome. RVFV is transmitted by mosquitoes and causes fever and severe hemorrhagic illness among humans, and fever and
high rates of abortions in livestock. A nonstructural RVFV NSs protein inhibits the transcription of host mRNAs, including
interferon-b mRNA, and is a major virulence factor. The present study explored a novel function of the RVFV NSs protein by
testing the replication of RVFV lacking the NSs gene in the presence of actinomycin D (ActD) or a-amanitin, both of which
served as a surrogate of the host mRNA synthesis suppression function of the NSs. In the presence of the host-
transcriptional inhibitors, the replication of RVFV lacking the NSs protein, but not that carrying NSs, induced double-
stranded RNA-dependent protein kinase (PKR)–mediated eukaryotic initiation factor (eIF)2a phosphorylation, leading to the
suppression of host and viral protein translation. RVFV NSs promoted post-transcriptional downregulation of PKR early in
the course of the infection and suppressed the phosphorylated eIF2a accumulation. These data suggested that a
combination of RVFV replication and NSs-induced host transcriptional suppression induces PKR-mediated eIF2a
phosphorylation, while the NSs facilitates efficient viral translation by downregulating PKR and inhibiting PKR-mediated
eIF2a phosphorylation. Thus, the two distinct functions of the NSs, i.e., the suppression of host transcription, including that
of type I interferon mRNAs, and the downregulation of PKR, work together to prevent host innate antiviral functions,
allowing efficient replication and survival of RVFV in infected mammalian hosts.
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Introduction
Rift Valley fever virus (RVFV) is a mosquito-borne zoonotic
pathogen, which is distributed in sub-Saharan Africa [1] and has
also caused large outbreaks in Madagascar [2], Egypt [3,4,5],
Saudi Arabia [6], and Yemen [6]. In endemic areas, RVFV
naturally circulates among mosquitoes and ruminants, such as
sheep, goat and cattle [7]. RVFV infection in adult ruminants
causes febrile illness and a high rate of abortions, while some
newborn animals less than 1–2 weeks of age develop an acute
infection which results in higher mortality rates than those in
adults [8]. Humans infected with RVFV usually develop an acute
febrile myalgic syndrome; however, a small percentage of patients
have a lethal illness that results in hepatic damage, hemorrhagic
fever-like illness, encephalitis and/or retinal vasculitis [8].
Due to the exotic origin of the virus, the potential for the aerosol
transmission [9,10,11,12] and serious consequences for humans
and livestocks, wild-type (wt) RVFV is classified as a Risk Group 3
pathogen, that needs to be handled in a high-containment facility,
e.g., a biosafety level (BSL)-4 laboratory, whereas a highly
attenuated MP-12 strain of RVFV, produced after 12 serial
passages of wt RVFV ZH548 in MRC-5 cells in the presence of 5-
fluorouracil [13], is a Risk Group 2 pathogen.
RVFV, which belongs to the genus Phlebovirus, family Bunyavir-
idae, is a negative-stranded RNA virus carrying a single-stranded,
tripartite RNA genome composed of S, M and L segments [14].
The S segment encodes N and NSs genes and uses an ambi-sense
strategy to express the N and NSs proteins in infected cells; N
mRNA encoding N protein is transcribed from the viral-sense
(negative-sense) S segment, while NSs mRNA encoding NSs
protein is transcribed from the antiviral-sense (positive-sense) S
segment. Monocistronic M mRNA and L mRNA are transcribed
from the viral-sense M and L segments, respectively. M mRNA
has one large open-reading frame (ORF) which encodes the
nonstructural NSm protein, a 78-kDa glycoprotein and two major
viral structural glycoproteins, Gn and Gc [15,16]. L mRNA
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N and L proteins are required for viral RNA synthesis, while Gn
and Gc function as envelope proteins [14]. NSm and NSs, both
nonstructural proteins, are dispensable for viral replication in cell
cultures [17,18,19,20], but are involved in viral pathogenesis
[21,22,23].
RVFV NSs protein is not essential for virus replication in cell
cultures [19,20], yet plays a critical role in viral virulence [21]. A
naturally occurring RVFV mutant Clone 13, which lacks
approximately 70% of the NSs gene [20], is highly attenuated in
mouse, and, when reassortant viruses between wt RVFV and
Clone 13 were characterized, the NSs was revealed as a major
determinant of viral virulence in the mouse model [21]. The NSs
localizes in the nucleus and cytoplasm in both RVFV-infected cells
and NSs-expressing cells; further, the nuclear NSs, but not the
cytoplasmic NSs, forms a unique filamentous structure [24]. The
NSs suppresses the transcription of host mRNAs by interacting
with the p44 subunit of TFIIH, an essential transcriptional factor
for cellular RNA polymerase II [25]. Furthermore, the RVFV NSs
binds to Sin3A-Associated Protein 30 (SAP30), which is important
for maintaining the repressor complex containing histone
deacetylase 3 on the interferon (IFN)-b promoter, and suppresses
the IFN-b promoter activation early in infection [26]. Accordingly,
the NSs protein in the nucleus of infected cells most probably
exerts these host transcriptional-suppressive activities, including
that of IFN production inhibition, and contributes to viral
virulence [21]. In contrast, the biological function of cytoplasmic
NSs is largely unknown. RVFV NSs expression promotes RVFV
minigenome RNA synthesis driven by N and L protein in
expression studies [27]. Because RNA synthesis of bunyaviruses
occurs in the cytoplasm, NSs protein in cytoplasm may promote
the minigenome RNA synthesis by unknown mechanism.
To establish that RVFV NSs exhibits a novel function, we
hypothesized that, when combined, RVFV replication and NSs-
induced host transcription suppression likely induces a cellular
environment that is unsuitable for viral replication. Thus, to secure
efficient RVFV replication, the NSs protein, in turn, alters this
putative, virally unfriendly cellular environment to one that
supports efficient viral replication. To test this possibility, we
examined the replication of RVFV lacking the NSs gene, a mutant
which was generated by employing a reverse genetics system [19],
in the presence of a host transcription inhibitor, e.g., actinomycin
D (ActD) or a-amanitin; these drugs were selected because they
mimicked the host transcriptional suppressive activities of the NSs.
Consistent with our supposition, RVFV lacking the NSs, but not
RVFV, failed to replicate efficiently in ActD-treated cells. We
noted that double-stranded RNA (dsRNA)-dependent protein
kinase (PKR)-mediated eukaryotic initiation factor (eIF)2a phos-
phorylation suppressed the translation of RVFV lacking NSs in the
presence of ActD. Further studies uncovered that RVFV NSs
promoted PKR downregulation as early as 4 hours post-infection,
and prevented eIF2a phosphorylation, which secured efficient
viral translation. We speculate that this novel function of RVFV is
important for counteracting the antiviral activities of PKR and
allowing efficient virus replication and survival in infected hosts.
Results
RVFV lacking the NSs undergoes poor viral protein
synthesis and viral replication in ActD-treated cells
To explore a novel biological function of RVFV NSs protein, in
addition to its host transcriptional shutoff activity, we investigated
the effect of ActD, a host transcriptional inhibitor, on the
replication of MP-12 lacking the NSs gene in IFN-incompetent
VeroE6 cells. VeroE6 cells were mock-infected or infected with
MP-12 or rMP12-rLuc, which expressed Renilla luciferase (rLuc) in
place of the NSs (Figure 1A) at a multiplicity of infection (moi) of 3.
After 1 h virus adsorption, cells were incubated in the absence or
presence of 5 mg/ml of ActD. Supernatants were harvested at
16 hours post-infection (h.p.i.), and virus titers were measured by
plaque assay. ActD treatment had little effect on MP-12 titers, yet
it significantly reduced the titer of rMP12-rLuc (Figure 1B), which
suggested that the RVFV NSs was important for an efficient virus
replication in the presence of ActD.
To understand how the NSs protein exerted an efficient viral
replication in the presence of ActD, we analyzed the status of host
and viral translation. VeroE6 cells were mock-infected or
independently infected with MP-12, rMP12-rLuc and rMP12-
C13type, the latter of which lacks approximately 70% of the NSs
ORF (Figure 1A), at an moi of 3. Cells were radiolabelled with
[
35S] Methionine/Cysteine from 15 to 16 h.p.i. Cell extracts were
prepared at 16 h.p.i., and the samples were applied to SDS-PAGE
(Figure 1C, top panel). In the absence of ActD, the host protein
synthesis of rMP12-rLuc-infected cells (Figure 1C, lane 5) and
rMP12-C13type-infected cells (Figure 1C, lane 7) was more
efficient than that of MP-12-infected cells (Figure 1C, lane 3). It is
possible that NSs-mediated transcriptional suppression that
occurred only in MP-12-infected cells, but not in cells infected
with viruses lacking NSs, caused a reduction of host mRNA
abundance, leading to the less efficient translation of host mRNAs
in MP-12-infected cells. Efficient N protein synthesis occurred in
cells infected with all three viruses in the absence of ActD, a
finding which was consistent with our previous studies [19], while
for some unknown reasons the accumulation of N proteins of
rMP12-rLuc and rMP12-C13type was slightly higher than that of
MP-12. ActD treatment resulted in a strong inhibition of both host
proteins and N protein synthesis in rMP12-rLuc-infected cells
(Figure 1C, lane 6) and rMP12-C13type-infected cells (Figure 1C,
lane 8). In contrast, ActD treatment did not inhibit N protein
translation in MP-12-infected cells; rather, it moderately inhibited
host protein synthesis in MP-12-infected cells (Figure 1C, lane 4).
A similar ActD-induced, moderate host protein synthesis inhibi-
Author Summary
The mosquito-borne bunyavirus Rift Valley fever virus
(RVFV) devastates both humans and domestic animals; it
causes abortions in ruminants and complications such as
hemorrhage, encephalitis, or retinal vasculitis in humans. A
major RVFV virulence factor, NSs, disables host cell mRNA
synthesis. Here we describe our new evidence that showed
NSs working in a second way; in addition to inhibiting host
cell transcription, NSs kept translation active in infected
cells. It is well-established that activated protein kinase PKR
phosphorylates a translation factor, eIF2a, and then this
phosphorylated eIF2a suppresses translation. We found
that NSs decreased PKR abundance and prevented eIF2a
phosphorylation in infected cells, allowing efficient viral
translation and replication. In contrast, when cells were
infected with an RVFV mutant lacking NSs in the presence
of transcriptional inhibitors that mimic the transcription
inhibition function of NSs, the PKR reduction did not occur
and phoshorylated eIF2a was accumulated, resulting in
the inhibition of virus gene expression and replication.
Thus, NSs functions in two ways to help RVFV replicate in
mammalian hosts: its newly identified PKR downregulation
function secures efficient viral translation, and its host
transcription inhibition function suppresses the expression
of host innate antiviral functions.
Novel Function of RVFV NSs Protein
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Western blot analysis of cell extracts at 16 h.p.i. clearly showed
that ActD treatment strongly inhibited N protein accumulation in
rMP12-rLuc-infected cells and rMP12-C13type-infected cells, but
not in MP-12-infected cells (Figure 1C, bottom panels). In
summary, ActD treatment had little effect on MP-12 replication,
whereas it strongly inhibited the expression of both host and viral
proteins in the cells infected with MP-12 lacking the NSs gene,
which resulted in poor virus production.
NSs protein expression promotes viral replication in
rMP12-rLuc–infected cells in the presence of ActD
To further confirm that the NSs exerted an efficient viral
replication in the cells that underwent ActD-induced host
transcriptional suppression, 293 cells, which showed higher RNA
transfection efficiencies than did VeroE6 cells (data not shown),
were infected with rMP12-rLuc at an moi of 2. After virus
adsorption, infected cells were mock-transfected or independently
transfected with in vitro-synthesized RNA transcripts encoding
chloramphenicol acetyltransferase (CAT), MP-12 NSs, or wt
RVFV ZH501 NSs. Then, the cells were mock-treated or treated
with ActD. Analysis of rLuc activities at 16 h.p.i. demonstrated
that NSs expression had little effect on rLuc activities in the
absence of ActD (Figure 2A). In the presence of ActD, rLuc
activities were clearly higher in the cells transfected with MP-12
NSs RNA transcripts or ZH501 NSs RNA transcripts than in
those transfected with CAT RNA transcripts or in the mock-
transfected samples (Figure 2A). In NSs RNA-transfected cells,
similar levels of rMP-12-rLuc titers were observed in both the
ActD-treated and mock-treated samples, whereas the rMP12-rLuc
virus titers in mock-transfected cells and CAT RNA-transfected
cells were significantly lower in the presence of ActD compared to
the ActD-untreated cells (Figure 2B). Western blot analysis showed
that NSs proteins were indeed expressed in the cells transfected
with RNA transcripts encoding MP-12 NSs or wt RVFV ZH501
NSs (Figure 2C, lanes 3, 4, 7, and 8). Also NSs protein expression
increased the accumulation of rMP12-rLuc N protein in the
presence of ActD (Figure 2C, lanes 7 and 8). These data
demonstrated that NSs exerted efficient rMP12-rLuc replication
in the presence of ActD. We noted that ActD treatment modestly
reduced the accumulation of the CAT protein (Figure 2C, lane 6).
Figure 1. Effects of ActD on the replication and protein synthesis of MP-12 and MP-12 lacking the NSs gene. (A) Schematic
representations of the S segments of MP-12, rMP12-rLuc, and rMP12-C13type. (B) Type I IFN-deficient VeroE6 cells were mock-treated or
independently infected with MP-12 and rMP12-rLuc at an moi of 3, immediately treated with ActD (5 mg/ml) or untreated, and culture fluids were
harvested at 16 h.p.i. Virus titers of MP-12 and rMP12-rLuc were measured by a plaque assay. The virus replication of rMP12-rLuc was significantly
reduced in the presence of ActD (*p,0.001; Student’s t-test). Data are expressed as mean+/2standard deviation of three independent experiments.
(C) Vero cells were mock-infected or independently infected with MP-12, rMP12-rLuc, and rMP12-C13type as described above. Cells were
radiolabelled with [
35S] labelled Methionine/Cysteine between 15 h.p.i. and 16 h.p.i. Cell extracts were prepared at 16 h.p.i. and applied to SDS-PAGE
(top panel). Intensities of signals in three separate areas (area 1, 2, and 3), which were determined by densitometric analysis, are shown at the bottom
of the top panel. Signal intensities of the mock-infected cells were used as the scale to measure the others and were considered as 100%. The
intensities of RVFV N proteins were also shown at the bottom of the top panel (N). The signal intensity of N protein in MP-12–infected cells in the
absence of ActD was represented as 100%. For Western blot analysis (middle and bottom panels), cell extracts from mock-infected cells and infected
cells were prepared at 16 h.p.i., and analyzed in a Western blot in which we used an anti-RVFV antibody (middle panel) and an anti–b-actin antibody
(bottom panel). Data are representative of three independent experiments.
doi:10.1371/journal.ppat.1000287.g001
Novel Function of RVFV NSs Protein
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introduced into the cells partly overcame the translational
suppressive effects that were induced by the combination of
rMP-12-rLuc replication and ActD treatment.
To test the possibility that ActD treatment alone suppressed
translation and RVFV NSs counteracted it, 293 cells were mock-
treated or treated with 5 mg/ml of ActD. We examined the
resulting polysome profiles at 16 h post–ActD treatment (Figure
S1A). Because ActD treatment at 5 mg/ml inhibits the transcrip-
tion mediated by RNA polymerases I, II and III [28], we expected
a reduction in the abundance of cellular mRNAs, tRNAs, and
ribosomal RNAs, leading to reduced abundances of polysomes.
ActD treatment indeed resulted in a reduced abundance of
polysomes, whereas it did not substantially alter the polysome
pattern, a finding which suggested to us that ActD treatment did
not abolish translational activities. To test the translational
competence of the cells treated with transcriptional inhibitors,
we transfected 293 cells with in vitro-synthesized RNA transcripts
encoding rLuc gene. Cells were mock-treated or treated with ActD
or a-amanitin, an RNA polymerase II inhibitor [29]. The rLuc
activities at 16 h post-transfection were slightly increased in the
cells treated with ActD or a-amanitin (Figure S1B), demonstrating
active host translation activities in the presence of either ActD or
a-amanitin. These data led to the suggestion that by combining
the replication of RVFV lacking the NSs and treatment of ActD, a
cellular condition that is unfavorable for translation could be
induced and that NSs expression somehow altered the cellular
environment from one that was translationally inactive to one
translationally active.
MP-12 replication promotes translation of rLuc mRNA of
rMP12-rLuc
To establish that NSs exerts an efficient viral translation in the
presence of a transcription inhibitor, we tested whether coinfection
of MP-12 and rMP12-rLuc increases the translation of rLuc
mRNA of rMP12-rLuc in the presence of ActD. VeroE6 cells were
mock-infected or co-infected with rMP12-rLuc and MP-12;
rMP12-rLuc was infected at an moi. of 2, while MP-12 was
infected at moi. of 0.1 or 1, as indicated in Figure 3. The cell
extracts were harvested at 16 h.p.i., and the rLuc activities
(Figure 3A) and accumulation of viral RNAs (Figure 3B) were
examined. As expected, ActD-treatment reduced the rLuc
Figure 2. Effects of NSs protein expression on the viral replication of rMP12-rLuc in the presence of ActD. 293 cells were infected with
rMP12-rLuc at an moi of 2, transfected with in vitro–synthesized RNA transcripts encoding CAT, MP-12 NSs, or ZH501 NSs, and treated with ActD or
were left untreated. Shown are the rLuc activities (A), virus titers (B), and protein accumulations (C) at 16 h.p.i. (A,B) The data were presented as
mean+/2standard deviation of three independent experiments, all of which had p values determined by using Student’s t-test (*p,0.05). (C) The
expression levels of N, NSs, CAT-myc-His, and b-actin were determined by Western blotting using anti-RVFV antibody (a-RVFV), anti-NSs antibody (a-
NSs), anti-myc antibody (a-Myc), and anti–b-actin antibody (a-b-actin), respectively. The data are representative of three independent experiments.
doi:10.1371/journal.ppat.1000287.g002
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PLoS Pathogens | www.plospathogens.org 4 February 2009 | Volume 5 | Issue 2 | e1000287Figure 3. Effect of MP-12 replication on translation of rLuc mRNA of rMP12-rLuc. VeroE6 cells were mock-infected, individually infected
with rMP12-rLuc and MP-12, or co-infected with both viruses at the moi indicated in the figure. ActD (5 mg/ml) was added immediately after infection,
and cell extracts were harvested at 16 h.p.i. (A) The rLuc activities are presented as mean+/2standard deviation of three independent experiments,
for which we determined the p values by using Student’s t-test (*p,0.05). (B) Northern blot analysis of S-segment RNA, N mRNA, and rLuc mRNA
using RNA probe specific to N mRNA and the antiviral-sense S-segment (N antisense) or rLuc mRNA (rLuc antisense). The data are the representative
of three independent experiments.
doi:10.1371/journal.ppat.1000287.g003
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infection of MP-12 resulted in the reduction of both rLuc activities
(Figure 3A) and the amounts of rLuc mRNA (Figure 3B, lane 4) in
the absence of ActD. In the presence of ActD, MP-12 co-infection
also reduced the rLuc mRNA abundance (Figure 3B, lane 9),
whereas it increased rLuc activities (Figure 3A). The results
suggested that NSs protein expressed from MP-12 S-segment
promoted an efficient translation of the rLuc mRNA of rMP12-
rLuc in the presence of ActD. We also noted that MP-12 co-
infection did not reduce the abundance of the viral-sense rMP-12-
rLuc S segment in the presence of ActD, and yet it caused the
reduction of rLuc mRNA abundance (Figure 3B, lane 9), which we
believe implies that NSs expression and ActD treatment generated
a cellular environment that was more favorable for rMP-12-rLuc
RNA replication than for transcription.
The status of eIF2a phosphorylation in infected cells
The dsRNAs generated during viral replication activate PKR,
which in turn phosphorylates eIF2a [30]. Also 59-triphosphated
single-stranded RNAs activate PKR [31]. The eIF2a is a
component of eIF2, which binds to GTP and Met-tRNA to
deliver the Met-tRNA to the start codon in capped mRNA,
forming a 43S pre-initiation complex [32]. Upon the binding of
the 60S ribosomal subunits to the 43S preinitiation complex, eIF2-
GDP is released from the ribosome and undergoes a GTP
exchange reaction catalyzed by binding with eIF2B, and the
resultant eIF2-GTP is recycled for the next round of translation
initiation. The phosphorylated eIF2a binds to eIF2B with a high
affinity and prevents eIF2B to be used for the subsequent eIF2-
GDP-to-eIF2-GTP exchange reaction, leading to the suppression
of translation initiation. Hence, the phosphorylation status of
eIF2a plays a critical role in translational control [32].
We suspected that rMP12-rLuc replication in the presence of
ActD may generate dsRNAs and/or 59-triphosphated single-
stranded RNAs, which activate PKR, resulting in the phosphor-
ylation of eIF2a. When we analyzed the level of eIF2a
phosphorylation in VeroE6 cells infected with rMP12-rLuc in
the absence of transcription inhibitor, we found low levels of eIF2a
phosphorylation from 8 to 24 h.p.i. and an efficient accumulation
of N protein at 8 h.p.i. and onward (Figure 4A–4C). In contrast,
when we treated rMP12-rLuc-infected cells with ActD or a-
amanitin, either compound induced an efficient accumulation of
phosphorylated eIF2a from 8 to 16 h.p.i., with a concomitant
poor N protein accumulation (Figure 4A–4C) and virus replication
suppression (Figure 4D). The mechanism of reduction in the
abundance of the phosphorylated eIF2a at 24 h.p.i. in the
presence of ActD or a-amanitin (Figure 4, lanes 13 and 19) is
unknown. When we treated rMP12-rLuc-infected cells with
different concentrations of ActD or a-amanitin, we found that
the inhibition of phosphorylated eIF2a accumulation was
dependent on the concentrations used (Figure S2). Also a strong
correlation was seen between an increase in eIF2a phosphoryla-
tion and the decrease in both N protein accumulation and
infectious virus production (Figure S2). In contrast, no significant
accumulation of phosphorylated eIF2a occurred in MP-12-
infected VeroE6 cells in the presence of ActD (Figure 4A–4C).
As expected, ActD treatment had little effect on MP-12 replication
(Figure 4D). These data strongly suggested that the presence of
highly phosphorylated eIF2a levels suppressed the translation of
viral mRNAs, leading to inefficient virus production, and that the
NSs protein somehow suppressed eIF2a phosphorylation, and
facilitated efficient viral mRNA translation under the conditions of
host transcriptional shutoff.
Because activated caspases 3, 7 and 8 can cleave PKR, releasing
the biologically active C-terminus kinase domain from the N-
terminus inhibitory domain, resulting in eIF2a phosphorylation
[33], we subsequently tested whether the accumulation of
phosphorylated eIF2a following the combined activity of viral
replication and ActD-treatment was due to induction of apoptosis
[34]. VeroE6 cells, either infected with rMP12-rLuc or mock-
infected, received the pan-caspase-inhibitor, benzyloxycarbonyl-
Val-Ala-DL-Asp(OMe) fluoromethylketone (Z-VADfmk), in the
presence of ActD or a-amanitin (Figure S3). Judging from the
resulting inhibition of cleaved caspase-3 accumulation in these
cells, the Z-VADfmk treatment indeed inhibited apoptosis,
whereas it had little effect on the eIF2a phosphorylation status
and infectious virus yield. These data suggested to us that the
accumulation of phosphorylated eIF2a in cells supporting rMP12-
rLuc replication in the presence of ActD or a-amanitin was
caspase-independent.
PKR exerts a critical role in eIF2a phosphorylation in
infected cells
Four different kinases, including PKR, PKR-like ER kinase
(PERK), heme-regulated inhibitor and the general control, non-
depressible-2 (GCN2), are known to phosphorylate eIF2a [35]. To
determine the role of PKR in the accumulation of phosphorylated
eIF2a in rMP12-rLuc-infected cells treated with ActD or a-
amanitin, we generated a recombinant MP-12, rMP12-PKRDE7,
which expresses a dominant-negative form of PKR, PKRDE7 [36]
carrying the N-terminal Flag epitope tag, in place of the NSs
(Figure 5A). If the replication of MP-12 lacking the NSs gene in
cells subjected to host transcriptional suppression activates PKR,
which in turn phosphorylates eIF2a, then the virally-encoded
PKRDE7 in rMP12-PKRDE7-infected cells would interfere with
the PKR function, resulting in the inhibition of PKR-mediated
eIF2a phosphorylation and thereby leading to efficient viral
translation and virus production. VeroE6 cells were mock-infected
or independently infected with rMP12-rLuc, rMP12-PKRDE7
and MP-12 at an moi of 3. After the removal of the inocula, cells
were treated with ActD or a-amanitin, and cell extracts were
harvested at 16 h.p.i. As expected, rMP12-rLuc replication in the
presence of ActD or a-amanitin induced eIF2a phosphorylation,
resulted in reduced virus replication (Figure 5B–5D). In contrast,
efficient N protein accumulation and efficient virus replication,
with no significant accumulation of phosphorylated eIF2a
occurred in both MP-12-infected cells and rMP12-PKRDE7-
infected cells in the presence of ActD- or a-amanitin (Figure 5B–
5D). This finding strongly suggested that PKR is important for
eIF2a phosphorylation in cells infected with the RVFV lacking the
NSs in the presence of transcription inhibitors.
To further confirm these data, viral protein accumulation and
replication were analyzed in wt mouse embryonic fibroblast (MEF)
cells and in Pkr
0/0 MEF cells lacking a functional PKR expression
[37]. MP-12 efficiently replicated in both wt MEF and Pkr
0/0 MEF
cells, and ActD treatment had little effect on N protein
accumulation and virus replication (Figure 5E, top and middle
panels). rMP12-rLuc replication was not as efficient as MP-12 in
wt MEF cells in the absence of ActD for an as yet unidentified
reason (Figure 5E, middle panel). In ActD-treated wt MEF cells,
both rMP-12-C13type and rMP12-rLuc failed to efficiently
accumulate N proteins, and rMP-12-rLuc replicated poorly,
whereas rMP-12-rLuc underwent efficient N protein accumulation
and viral replication in ActD-treated Pkr
0/0 MEF cells (Figure 5E,
top and middle panels). Furthermore, accumulation of phosphor-
ylated eIF2a did not occur in Pkr
0/0 MEF cells that were infected
with rMP12-rLuc in the presence of transcriptional inhibitors
Novel Function of RVFV NSs Protein
PLoS Pathogens | www.plospathogens.org 6 February 2009 | Volume 5 | Issue 2 | e1000287Figure 4. Status of eIF2a phosphorylation in rMP12-rLuc–infected cells and MP-12–infected cells in the presence of transcriptional
inhibitors. VeroE6 cells were mock-infected (M) or infected with rMP12-rLuc or MP-12 at an moi of 3, and then immediately treated with ActD (5 mg/
ml) or a-amanitin (50 mg/ml), or left untreated (No drug). Samples were harvested at the indicated time points post-infection for Western blot analysis
or virus titration. The data shown in the graphs (mean+/2standard deviation) were obtained from three independent experiments with p values
determined using Student’s t-test (*: p,0.05 compared to No drug at each time point). (A) Western blot analyses of RVFV N protein, phosphorylated
eIF2a, total eIF2a, and b-actin. The data are representative of three independent experiments. (B) The relative abundance of phosphorylated eIF2a
and total eIF2a at various times post-infection. The relative abundance of phosphorylated eIF2a normalized to total eIF2a at 0 h.p.i. is represented as
100%. (C) Accumulation of N protein at various times p.i. The abundance of N protein at 4 h p.i represented as 100% for each of three groups. (D)
Kinetics of virus titers in the culture fluids of the infected cells.
doi:10.1371/journal.ppat.1000287.g004
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PLoS Pathogens | www.plospathogens.org 7 February 2009 | Volume 5 | Issue 2 | e1000287Figure 5. Role of PKR in eIF2a phosphorylation in infected cells under transcriptional suppression. VeroE6 cells (B,C,D), wild-type MEF
cells, or Pkr
0/0 MEF cells (E) were independently infected with MP-12, rMP12-rLuc, and rMP12-PKRDE7 at an moi of 3, or were mock-infected. Cells
were immediately treated with 5 mg/ml of ActD (Act) or 50 mg/ml of a-amanitin (Ama), or were untreated. Cell extracts were prepared at 16 h.p.i. for
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notion that PKR triggered the accumulation of phosphorylated
eIF2a in cells infected with the MP-12 lacking the NSs, under the
conditions of cellular transcriptional suppression, and the NSs
protein interfered with the PKR-mediated eIF2a phosphorylation
(Figure 5B–5D).
Testing the possible NSs-mediated suppression of PKR
phosphorylation
To know how the NSs suppressed the eIF2a phosphorylation
activity of the PKR function, a dsRNA-binding assay was
performed to test the possibility that the NSs binds to dsRNA,
sequesters dsRNA from PKR, and interferes with the dsRNA-
mediated PKR activation. 293 cells were mock-infected or infected
with rMP12-NSs-Flag carrying Flag-tagged NSs, rMP12-rLuc-
Flag carrying Flag-tagged rLuc (Figure 6A) or rMP12-PKRDE7
(Figure 5A). In a separate experiment, 293 cells were transfected
with in vitro-synthesized RNA transcripts encoding NSs. Lysates
were prepared at 16 h.p.i. or 16 h post-transfection, and
incubated with poly I:C beads (dsRNA) or poly (C) beads (ssRNA).
Then the dsRNA-bound complexes were analyzed by a Western
blot in which we used an anti-Flag antibody or anti-NSs antibody
(Figure 6B). As expected, dsRNA bound to PKRDE7 [36],
whereas it poorly bound to the NSs from rMP12-NSs-Flag-
infected cells and that from the NSs-expressing cells (Figure 6B),
which suggested that NSs did not suppress PKR activation by its
binding to dsRNA.
Because activated PKR undergoes a structural alteration and
autophosphorylation [30], we tested whether NSs prevented PKR
autophosphorylation. 293 cells were infected with rMP12-NSs-
Flag, rMP12-rLuc-Flag or rMP12-PKRDE7, and mock-treated or
immediately treated with ActD. Cell lysates were harvested at
16 h.p.i., and PKR was immunoprecipitated by anti-human PKR
antibody, and the PKR bound to the protein A beads was
subjected to an immunoprecipitation (IP)-kinase assay by using
[c-
32P]ATP. We used 293 cells for this assay, because anti-human
PKR antibody efficiently immunoprecipitated human PKR in 293
cells, but not non-human primate PKR in VeroE6 cells (data not
shown). PKR is induced by IFN-a/b treatment [38] and the
abundance of PKR could affect the results of the IP-kinase assay.
We suspected that replication of MP-12 mutants lacking NSs may
induce IFN-b production, leading to PKR induction [38], whereas
ActD treatment prevented the IFN-b production [39]. Indeed,
IFN-b mRNA accumulation occurred at 8 h.p.i. in rMP-12-rLuc-
infected cells in the absence of ActD, but not in the presence of
ActD (Figure 6C), a finding which suggested that ActD treatment
inhibited the transcriptional induction of PKR which was induced
by the type I IFN in infected 293 cells. We noted an efficient
accumulation of rMP12-rLuc N mRNA at 8 h.p.i. in the presence
of ActD (Figure 6C). Because rMP-12-rLuc replication in the
presence of ActD did not induce an accumulation of phosphor-
ylated eIF2a early in the course of the infection (Figure 4A), this
efficient rMP12-rLuc replication probably occurred prior to
8 h.p.i. in the presence of ActD. As shown in Figure 6D,
immunoprecipitated PKR from rMP12-rLuc-Flag-infected cells
was phosphorylated both in the presence and absence of ActD,
which led us to suggest that rMP12-rLuc-Flag replication activated
PKR. In contrast, PKR phosphorylation did not occur in mock-
infected cells or cells infected with rMP12-NSs-Flag or rMP12-
PKRDE7 (Figure 6D). Most probably, a dominant-negative
PKRDE7 suppressed PKR activation and prevented PKR
phosphorylation [36]. To determine why we failed to detect the
presence of PKR autophosporylation in rMP12-NSs-Flag-infected
cells, we examined the amounts of the immunoprecipitated PKR
in these samples (Figure 6D, bottom). Strikingly, substantial
reductions in the abundance of cytoplasmic PKR occurred only in
the cells supporting rMP12-NSs-Flag replication both in the
presence and absence of ActD.
RVFV NSs promotes PKR downregulation
We subsequently tested the possibility that the NSs downreg-
ulated PKR expression or sequestered PKR into the nuclear
compartment, leading to the suppression of eIF2a phosphoryla-
tion. 293 cells were mock-infected or infected with rMP12-NSs-
Flag, rMP12-rLuc-Flag or rMP12-PKRDE7, treated with ActD,
and cytoplasmic and nuclear fractions of cell extracts were
prepared at 16 h.p.i. Western blot analyses showed the presence
of RVFV NSs both in the cytoplasmic and nuclear fractions, while
rLuc and PKRDE7 signals were observed only in the cytoplasmic
fraction. A substantial reduction in PKR abundance occurred in
both the cytoplasmic and nuclear fractions of cells infected with
rMP-12-NSs-Flag, but not in mock-infected cells and in those
infected with rMP12-rLuc-Flag or rMP12-PKRDE7 (Figure 7A),
demonstrating that NSs induced the PKR downregulation in the
infected cells. The PKR downregulation also occurred in MP-12-
infected VeroE6 cells and in MRC-5 cells that were infected with
the wt ZH501 strain of RVFV (data not shown).
To determine whether NSs expression alone induces PKR
downregulation, 293 cells were mock-infected or infected with
rMP12-rLuc, immediately transfected with in vitro-synthesized
RNA transcripts encoding rLuc or NSs, and treated with ActD
(Figure 7B, left panel). Cells were harvested at 16 h post-
transfection. The clear reduction in the PKR abundance occurred
in mock-infected cells expressing NSs, but not in those expressing
rLuc (Figure 7B, left panel), demonstrating that NSs protein alone
exerted the PKR downregulation.
We subsequently examined the requirement of the ActD
treatment for the PKR downregulation. 293 cells were transfected
with in vitro-synthesized RNA transcripts encoding NSs or rLuc in
the absence of ActD. Analysis of cell extracts harvested at 8 h post-
transfection showed the PKR downregulation in the NSs-
expressing cells (Figure 7B, right panel), demonstrating that the
NSs-mediated PKR downregulation occurred in the absence of
ActD.
To further understand the mechanism of the NSs-mediated
PKR downregulation, we examined whether NSs expression
Western blot analysis (B,E), and culture fluids were collected for virus titration (D,E). The data shown in the graphs (mean+/2standard deviation) were
obtained from three independent experiments with p values of Student’s t-test (*: p,0.05). The Western blot data is representative of three
independent experiments. (A) Schematic representations of S segments of MP-12, rMP12-rLuc, and rMP12-PKRDE7. (B) Western blot analysis showing
the accumulation of eIF2a, phosphorylated eIF2a, N protein, NSs protein, Flag-PKRDE7, and b-actin in infected VeroE6 cells. (C) Relative abundance of
phosphorylated eIF2a and total eIF2a are shown in (B). The relative abundance of phosphorylated eIF2a and total eIF2a in mock-infected, untreated
cells represents 100%. (D) Virus titers of rMP12-rLuc, rMP12-PKRDE7, or MP-12 in VeroE6 cells. (E) Accumulation of RVFV N proteins and b-actin in wild-
type MEF cells or in Pkr
0/0 MEF cells. M represents mock-infected cells. Middle left panel and middle right panel represent virus titers in wild-type MEF
cells and in Pkr
0/0 MEF cells, respectively. The bottom panel shows the amounts of total eIF2a, phosphorylated eIF2a and b-actin in mock-infected
cells (Mock), MP-12 infected cells, and rMP12-rLuc–infected cells in the presence of 5 mg/ml of ActD (Act), 50 mg/ml of a-amanitin (Ama), or in the
absence of the drugs (M).
doi:10.1371/journal.ppat.1000287.g005
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transfected or transfected with in vitro-synthesized RNA tran-
scripts encoding NSs or rLuc. Then the cells were mock-treated or
treated with ActD. Total RNAs were harvested at 8 h post-
transfection and the expression levels of PKR mRNA were
examined by quantitative real-time reverse transcription polymer-
ase chain reaction (RT-PCR) analysis (Figure 7C). The relative
expression levels of PKR mRNA were significantly increased in
cells that were transfected with rLuc RNA transcripts or NSs RNA
transcripts both in the absence and presence of ActD, which
demonstrated to us that NSs expression did not promote the
degradation of PKR mRNA. Efficient ActD-mediated suppression
of IFN-b mRNA accumulation in rMP-12-rLuc-infected 293 cells
(Figure 6C) led us to suggest that unexpected increases in the
abundance of PKR mRNA in the RNA-transfected 293 cells in the
presence of ActD were IFN-b-independent. We suspect that the
RNA transcripts that were taken up by the cells induced robust
PKR mRNA synthesis prior to ActD- or NSs-mediated general
transcription suppression.
Since NSs expression did not decrease the abundance of PKR
mRNA (Figure 7C), we next tested whether putative NSs-
mediated translational inhibition leads to a reduction in the
abundance of PKR. To this end, 293 cells were mock-infected,
infected with MP-12, or transfected with in vitro-synthesized RNA
transcripts encoding NSs. Then cells were incubated with 100 mg/
ml of puromycin to completely shut off cellular translation or
puromycin untreated, and cell extracts were harvested at 16 h.p.i.
or post-transfection. As expected, puromycin treatment completely
abolished the synthesis of N and NSs proteins in MP-12-infected
cells (Figure 7D, lane 4) and that of NSs in cells transfected with
the RNA transcripts encoding NSs (Figure 7D, lane 6). We found
that treatment of 293 cells with puromycin for 16 h decreased the
abundance of PKR only slightly (Figure 7D, lane 2). Accordingly,
it is highly unlikely that putative NSs-induced translational
Figure 6. Testing dsRNA binding activity of NSs protein and autophosphorylation of PKR in infected cells. (A) Schematic
representations of RVFV S segments of rMP12-NSs-Flag and rMP12-rLuc-Flag. (B) 293 cells were mock-infected (Mock) or infected with rMP12-rLuc-
Flag, rMP12-NSs-Flag, or rMP12-PKRDE7 at an moi of 3 (left panel). In the right panel, 293 cells were transfected with in vitro–synthesized RNA
transcripts encoding RVFV MP-12 NSs. At 16 h.p.i. or 16 h post-transfection, cytoplasmic lysates (L) were incubated with poly C (pC) beads or poly I:C
(pIC) beads. The dsRNA binding activity of the NSs was analyzed as described in Materials and Methods. Proteins bound to beads were analyzed by
Western blotting using anti-Flag antibody (left panel) or anti-NSs antibody (right panel). Asterisk (*) represents the NSs. (C) 293 cells were infected
with rMP12-rLuc or MP-12 at an moi of 3. After infection, cells were mock-treated (2) or immediately treated with ActD (+)a t5mg/ml. Total RNA was
harvested at 8 h.p.i., and accumulations of IFN-b mRNA, antiviral-sense S segment RNA, N mRNA, and GAPDH mRNA were analyzed by Northern blot.
(D) 293 cells were mock-infected or infected with rMP12-NSs-Flag, rMP12-rLuc-Flag, or rMP12-PKRDE7 at an moi of 3, and, then, cells were mock-
treated (No drug) or immediately treated with 5 mg/ml of ActD. A cytoplasmic fraction was collected at 16 h.p.i. and the IP-kinase assay of PKR was
performed as described in Materials and Methods (top panel). A part of samples was used for Western blot analysis by using anti-PKR monoclonal
antibody to show the abundance of immunoprecipitated PKR (bottom panel). Data are representative of two independent experiments (B–D).
doi:10.1371/journal.ppat.1000287.g006
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PLoS Pathogens | www.plospathogens.org 10 February 2009 | Volume 5 | Issue 2 | e1000287Figure 7. Analysis of NSs-induced PKR downregulation. (A) 293 cells were mock-infected (Mock) or independently infected with rMP12-NSs-
Flag, rMP12-rLuc-Flag, and rMP12-PKRDE7 at an moi of 3. Cells were immediately treated with 5 mg/ml of ActD, and both cytoplasmic (C) and nuclear
(N) fractions were collected at 16 h.p.i. Results are shown of Western blot analysis performed by using anti-PKR antibody, anti-Flag antibody, anti–b-
actin antibody, and anti-Histone H1 antibody. (B) 293 cells were mock-infected (Mock) or infected with rMP12-rLuc at an moi of 3. Then cells were
mock-transfected (M) or transfected with in vitro–synthesized RNA transcripts encoding rLuc (rLuc) or NSs (NSs). Cells were then treated with 5 mg/ml
of ActD. Whole-cell lysates were collected at 16 h.p.i. (left panel). Another set of cells were mock-transfected or transfected with in vitro–synthesized
RNA transcripts encoding NSs or rLuc, and cell extracts were harvested at 8 h post-transfection (right panel). Western blot analysis was performed by
using anti-PKR antibody, anti-RVFV antibody, and anti–b-actin antibody. Lane 10 represents the cell lysate of rMP12-rLuc–infected cells harvested at
8 h.p.i. in the absence of ActD. (C) 293 cells were mock-transfected or transfected with in vitro–synthesized RNA transcripts encoding MP-12 NSs or
rLuc. Cells were mock-treated or treated with 5 mg/ml of ActD. Total RNA was harvested at 8 h post-transfection, and analyzed by real-time PCR. The
relative abundance of PKR mRNA of each sample was calculated by the DDCT method based on the abundance of 18S ribosomal RNA. The data
shown in the graph (mean+/2standard deviation) were obtained from three independent experiments. The p value was determined by Student’s t-
test (*: p,0.05). (D) 293 cells were mock-infected (Mock) or infected with MP-12 at an moi of 3 or transfected with in vitro–synthesized RNA
transcripts encoding NSs. Cells were then mock-treated or treated with 100 mg/ml of puromycin. Cell extracts were harvested at 16 h.p.i. or 16 h post-
transfection, and the abundance of PKR and viral proteins were analyzed by Western blotting with anti-PKR antibody (top panel), anti-RVFV antibody
(middle panel), or anti–b-actin antibody (bottom panel). (E) 293 cells were mock-transfected or transfected with pcDNA3.1-Myc-PKRK296R. Cells were
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abundance.
We next performed pulse-chase experiments to know whether
NSs expression promoted PKR degradation. Because immuno-
precipitation experiments using various anti-PKR antibodies failed
to convincingly demonstrate a radiolabelled endogenous PKR
signal from extracts of 293 cells (data not shown), we examined the
effect of NSs expression on the stability of an expressed mutant
PKR, PKRK296R, lacking kinase activity [40] and carrying a N-
terminal myc tag; expression of wild-type PKR was not used due
to its strong host translation suppression effects (data not shown).
293 cells were mock-transfected or transfected with pcDNA3.1-
Myc-PKRK296R, a plasmid encoding PKRK296R under
cytomegalovirus promoter and radiolabelled with [
35S] methio-
nine/cycteine between 14 and 16 h post–DNA transfection. After
pulse-radiolabelling cell extracts were prepared from some
samples. In other samples, cells were transfected with in vitro-
synthesized RNA transcripts encoding rLuc or NSs, and cell
extracts were harvested at 8 h post–RNA transfection. Then the
cell extracts were subjected to radioimmunoprecipitation analysis
using anti-myc antibody, which immunoprecipitated the pulse-
radiolabelled, myc-tagged PKR (Figure 7E, lane 2). After 8 h
chase, the amount of the radiolabelled myc-tagged PKR was
clearly reduced in the cells expressing NSs (Figure 7E, lane 4), but
not those expressing rLuc (Figure 7E, lane 3). Instead, the amount
of radiolabelled myc-tagged PKR was increased slightly in rLuc-
expressing cells, presumably due to radiolabelling of continuously
synthesized myc-tagged PKR by residual [
35S] methionine/
cysteine.
The complete shutoff of cellular translation by puromycin for
16 h did not result in the loss of endogenous PKR (Figure 7D),
whereas as early as 8 h post-transfection of RNA transcripts
encoding NSs, the abundance of PKR decreased substantially
(Figure 7B) without reducing the abundance of PKR mRNA
(Figure 7C). Furthermore, NSs expression reduced the abundance
of myc-tagged PKR that had been radiolabelled prior to NSs
expression (Figure 7E). These data strongly suggested that NSs
induced the downregulation of PKR at a post-transcriptional level
and pointed to a possibility that the NSs promoted PKR
degradation.
We next tested whether RVFV NSs downregulated PKR by
promoting PKR degradation through a ubiquitin-proteasome
pathway. 293 cells were infected with rMP12-rLuc or MP-12, and
were immediately treated with proteasome inhibitor MG132 or
lactacystin. Cells were harvested at 8 h.p.i. and analyzed in
Western blotting. As expected, rMP12-rLuc replication did not
induce PKR downregulation (Figure 7F, lane 1), while MP-12
replication induced the reduction of PKR abundance (Figure 7F,
lanes 4). It was evident that the treatment of MP-12-infected cells
with those proteasome inhibitors suppressed NSs-induced PKR
downregulation (Figure 7F, lanes 5 and 6), suggesting that NSs
promoted PKR downregulation by the degradation through the
proteasome pathway.
Phorbol 12-myristate 13-acetate (PMA), a potent activator of
protein kinase C (PKC), induces PKR degradation [41]. Because
the general PKC inhibitor, GO ¨ 6983, suppresses PMA-mediated
PKR degradation [41], we examined whether the NSs promoted
PKR downregulation through PKC by treating MP-12-infected
cells with GO ¨ 6983. Treatment of GO ¨ 6983 did not inhibit the
NSs-mediated PKR downregulation (Figure 7F, lane 8), suggesting
that PKC was not involved in NSs-induced PKR downregulation.
To know how quickly PKR downregulation occurred in MP-12-
infected cells, whole-cell extracts were prepared at 2, 4, 6 and
8 h.p.i. from MP-12-infected 293 cells and the amounts of NSs
and PKR were determined (Figure 7G). In the absence of
proteasome inhibitor, a substantial reduction of PKR abundance
occurred as early as 4 h.p.i., where the abundance of NSs
(Figure 7G, lane 2) was not as great as that at 8 h.p.i. (Figure 7G,
lane 4). In the presence of MG132, the abundance of PKR
decreased only slightly, and NSs accumulation was also somewhat
less efficient. A similar trend for less efficient NSs accumulation in
the presence of proteasome inhibitors was also shown in the data
for Figure 7F. Our observation of less efficient NSs accumulation
in MG132-treated cells was consistent with the report that MG132
induces eIF2a phosphorylation through GCN2 activation and
translational suppression [42]. The abundance of NSs in MG132-
treated cells at 8 h.p.i. and that in untreated cells at 4 h.p.i. was
similar, and yet PKR abundance in the former cells was clearly
higher than that in the latter cells. Taken together, these data
strongly suggested that RVFV NSs promoted PKR degradation
through the proteasome-dependent pathway.
Discussion
Biological significance of NSs-mediated PKR
downregulation
The present study explored a novel function of the RVFV NSs
protein by testing the replication of RVFV lacking the NSs gene
initially in type I IFN-incompetent VeroE6 cells [43,44] in the
presence of ActD or a-amanitin, which served as a surrogate of the
host mRNA synthesis suppression function of the NSs. The NSs
protein was essential for efficient virus replication in the presence
of ActD or a-amanitin. We found that the replication of RVFV
lacking the NSs gene in the presence of a transcription inhibitor
induced an accumulation of phosphorylated eIF2a, The accumu-
lation of phosphorylated eIF2a in the presence of transcriptional
inhibitors, did not occur in VeroE6 cells that were infected with
RVFV expressing a dominant-negative form of PKR (PKRDE7)
and in MEF cells lacking functional PKR (Figure 5). These
findings suggested to us that PKR played a major role in
increasing phosphorylated eIF2a; however, it is currently unclear
whether other kinases, such as PERK or GCN2, have a possible
role in eIF2a phosphorylation in rMP-12-rLuc-infected cells in the
presence of transcriptional inhibitors. The endogenous PKR-
mediated eIF2a phosphorylation suppressed translation of the
RVFV lacking the NSs gene, resulting in poor virus replication.
Our data further suggested that the NSs promoted PKR
degradation most probably through a proteasome-dependent
pathway and prevented eIF2a phosphorylation, leading to efficient
viral translation.
radiolabelled with [
35S] Methionine/Cysteine between 14 and 16 h post-transfection. Then, cells were harvested (0 h), or transfected with in vitro–
synthesized RNA transcripts encoding rLuc or MP-12 NSs. At 8 h post–RNA transfection, cells were harvested (8 h). Radiolabelled myc-tagged PKR was
immunoprecipitated by anti-myc monoclonal antibody, analyzed by SDS-PAGE with 7.5% poryacrylamide gel, and visualized by autoradiography. (F)
293 cells were infected with rMP12-rLuc or MP-12 at an moi of 3, and, then, treated with 10 mM of MG132 (MG) or 50 mM of lactacystin (LA) or they
were mock-treated (2). Whole-cell lysates were collected at 8 h.p.i., and the abundance of PKR, NSs and b-actin were examined by Western blot
analysis. (G) 293 cells were mock-infected (Mock) or infected with MP-12 (MP-12) at an moi of 3, and treated with MG132 (MG132) at 10 mM or they
were untreated (no drug used). Whole-cell lysates were collected at 2, 4, 6, and 8 h.p.i. Anti-PKR antibody, anti-NSs antibody, and anti–b-actin
antibody were used to detect PKR, NSs, and b-actin, respectively (F and G). Data are representative of two to three independent experiments (A–G).
doi:10.1371/journal.ppat.1000287.g007
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illustrate that two distinct biological activities of the RVFV NSs
protein worked together to secure efficient RVFV replication.
Namely, nuclear NSs protein inhibits transcription of host
mRNAs, including the IFN mRNAs; this activity is critical for
efficient RVFV replication in IFN-competent systems [25,45].
However, a combination of RVFV replication and NSs-mediated
host mRNA transcriptional suppression possibly induces PKR
activation and subsequent eIF2a phosphorylation as a combina-
tion of RVFV replication and ActD or a-amanitin treatment
induced it. The NSs protein, in turn, promotes PKR downreg-
ulation as early as 4 h.p.i., and prevents eIF2a phosphorylation to
secure the translation of viral mRNAs and efficient virus
replication. We think that both of these two NSs functions are
tightly related and protect efficient viral replication by suppressing
host antiviral responses. In RVFV-infected cells, the NSs
establishes general transcriptional suppression at a later stage of
infection (after 8 h.p.i.) [25], while NSs also suppresses specific
IFN-b mRNA transcription at early stages of infection (about
3 h.p.i.) by maintaining repressor complex including SAP30 on
IFN-b promoter [26,45]. PKR downregulation early in infection is
probably important for maintaining efficient viral translation in
combination with the suppression of host IFN responses.
We suspect that the NSs-mediated PKR downregulation activity
is important for RVFV replication and survival in infected
mammalian hosts. RVFV-infection in rhesus monkeys showed
that type I IFN is detectable around 1 day post-infection in both
clinically ill surviving monkeys and lethally infected monkeys, and
one dead monkey even kept high titer of IFN (120 to 480 U/ml)
from 1 day post-infection [46]. In fact, the best correlation with
outcome was early detection of IFN and not necessarily the height
of the response. NSs suppresses IFN-b mRNA transcription early
in the course of infection in cultured cells [26,45]. Our present
data suggest that the early downregulation of PKR in RVFV-
infected cells might contribute to the inhibition of type I IFN
induction, because PKR is known to serve as a pathogen-
recognition receptor [47]. Furthermore, some of the host
pathogen-recognition receptors, e.g., toll-like receptors 3 and 7,
in uninfected cells located near the RVFV-infected cells, recognize
virus-specific signals, e.g., viral RNAs in the virus particles or viral
dsRNAs in the cell debris from infected cells, leading to type I IFN
production. Because the transcriptional promoter of the PKR gene
contains an IFN-stimulated response element, and IFN stimulation
induces PKR mRNA transcription [38], PKR abundance is likely
increased in many uninfected cells of infected animals; RVFV
needs to replicate in such cells to survive in infected hosts. The
reduction in PKR abundance occurred as early as 4 h.p.i.
(Figure 7G) and the NSs protein is produced very early in RVFV
infection [48]. Immediate NSs synthesis and subsequent NSs-
induced PKR downregulation in the cells, some of which have
increased PKR abundance, could rapidly disarm the PKR-
mediated, antiviral functions and contribute to RVFV replication
and survival in animal hosts.
Possible mechanisms of the accumulation of
phosphorylated eIF2a in ActD-treated, rMP12-rLuc–
infected cells
ActD treatment of uninfected cells resulted in a significant
reduction of the polysome fraction, but it did not abolish the
translational activities (Figure S1). rMP12-rLuc replication in the
cells treated with ActD or a-amanitin promoted the accumulation
of the phosphorylated eIF2a, resulting in translational suppression
of viral proteins (Figure 4). The increased amounts of phosphor-
ylated eIF2a clearly correlated with the concentration of ActD or
a-amanitin in rMP12-rLuc-infected cells (Figure S2). In contrast,
rMP12-rLuc replication in the absence of transcriptional suppres-
sor induced only low levels of eIF2a phosphorylation (Figure 4).
Yet, the phosphorylation of PKR occurred in cells supporting the
replication of RVFV lacking NSs both in the absence and presence
of ActD (Figure 6D). Thus, a significant accumulation of
phosphorylated eIF2a occurred only in cells in which replication
of RVFV lacking NSs was combined with the treatment with
transcriptional inhibitors.
Several different mechanisms are conceivable for the accumu-
lation of phosphorylated eIF2a in rMP12-rLuc-infected in cells
treated with ActD or a-amanitin (Figure 4). One possible
mechanism relates to the eIF2a dephosphorylation step. Phos-
phorylation of eIF2a at Serine 51 induces a rapid synthesis of
activating transcription factor (ATF)-4 mRNA, which can be
translated in the presence of phosphorylated eIF2a [49].
Expressed ATF4 then induces GADD34 mRNA transcription
[50] and GADD34 protein interacts with type 1 protein serine/
threonine phosphatase, PP1, and this complex dephosphorylates
eIF2a to resume the cellular translation [51]. rMP12-rLuc
replication in transcriptionally active cells probably induced
PKR activation and eIF2a phosphorylation, the latter of which
then induced GADD34 upregulation and subsequent eIF2a
dephosphorylation allowing efficient viral translation. rMP12-
rLuc replication in cells treated with ActD induced PKR
activation, the extent of which was similar to that of infected,
ActD-untreated cells (Figure 6D), whereas the transcription
inhibitors would prevent GADD34 upregulation and subsequent
eIF2a dephosphorylation, causing an accumulation of phosphor-
ylated eIF2a, which inhibited viral translation. Other possible
mechanisms relate to the failure to suppress the PKR function.
Cells infected with adenovirus, human immunodeficiency virus-1,
or herpes simplex virus undergo a dramatic increase in the
abundance of Alu RNA, which carries a repetitive element of
,300-nt in length that is transcribed by RNA polymerase III
[52,53,54,55]. Alu RNA forms a stable complex with PKR, and
antagonizes the PKR activation [56]. If rMP12-rLuc replication
induces Alu RNA accumulation to prevent PKR activation, then
the drug-induced transcriptional suppression would inhibit Alu
RNA accumulation, preventing Alu RNA-mediated PKR inacti-
vation. Another possibility is that rMP12-rLuc replication
transcriptionally induces host mRNAs, and some of their gene
products have PKR inhibition activities. An example of this
possibility is that influenza virus replication induces P58
IPK,a n
inhibitor of PKR [57]. ActD or a-amanitin treatment suppresses
the expression of the putative PKR inhibitor, resulting in an
accumulation of phosphorylated eIF2a. Alternatively, transcrip-
tional suppression may result in reduced amounts of ribosomal
proteins, such as L18, which binds to PKR and inhibits PKR
activation [58,59]. These possibilities are not mutually exclusive,
and the combination of these possibilities may contribute to the
accumulation of phosphorylated eIF2a in the cells supporting
replication of RVFV lacking the NSs in the presence of ActD or a-
amanitin.
Possible mechanisms of the NSs-mediated PKR
downregulation
Although many viruses suppress PKR function using various
strategies [32], poliovirus is known to promote PKR degradation
in infected cells [60,61]; poliovirus RNA and viral protein
components are required for this activity [61], and both eIF2a
and PKR are highly activated in poliovirus-infected cells before
PKR downregulation occurs [60]. In contrast to poliovirus, only
RVFV NSs protein was probably required for PKR downregu-
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4 h.p.i. in RVFV-infected cells (Figure 7G), whereas phosphory-
lated eIF2a accumulation occurred around 8 h.p.i. in rMP-12-
rLuc-infected cells in the presence of ActD (Figure 4). Further-
more, NSs downregulated PKRK296R, a non-phosphorylatable
mutant PKR (Figure 7E). These data suggest that the phosphor-
ylation of PKR was not essential for the NSs-mediated PKR
downregulation.
A substantial reduction in the abundance of PKR occurred in
both the cytoplasmic and nuclear fractions of MP-12-infected cells,
but not in the mock-infected cells and in those infected with MP12
lacking NSs (Figure 7). Expression of NSs alone resulted in a
reduction in the amount of PKR (Figure 7B). These data
established that NSs protein induced PKR downregulation. The
NSs-induced PKR downregulation occurred as early as 4 h.p.i. of
MP-12 (Figure 7G). We also demonstrated the presence of PKR
mRNA in NSs-expressing cells (Figure 7C) and that ActD
treatment had little effect on the NSs-induced PKR downregula-
tion (Figure 7B). We failed to detect PKR at 16 h.p.i. of MP-12-
infected 293 cells, and yet we easily detected the PKR after a 16 h-
long incubation of 293 cells with puromycin (Figure 7D).
Accordingly, the putative NSs-induced translational inhibition
was not a main reason for the reduction in the abundance of PKR.
Furthermore, pulse-chase experiments showed that NSs expression
reduced the abundance of radiolabelled myc-tagged PKR
(Figure 7E). All of these data strongly suggested that the NSs
induced PKR downregulation at post-transcriptional levels.
It was reported that treatment of a macrophage cell line with
IFN-c induced PKR degradation [62]. Because NSs induced PKR
degradation in ActD-treated cells and ActD treatment completely
inhibited the IFN-c mRNA accumulation (Figure 6C), it is highly
unlikely that IFN-c was involved in the NSs-induced PKR
downregulation. PKC activation also potentially induces PKR
downregulation [41]. Treatment of MP-12-infected cells with a
PKC inhibitor, GO ¨ 6983, did not inhibit NSs-mediated PKR
downregulation (Figure 7D), which implied that PKC was not
involved in it. Experiments using a proteasome inhibitor suggested
that the NSs promoted PKR degradation through a proteasome
pathway (Figure 7F). MG132 can induce GCN activation and
translational suppression [42]. In fact, treatment of MP-12-
infected cells with MG132 and lactacystin moderately reduced
the accumulation of NSs (Figure 7F and 7G). Accordingly, a
possibility still exists that the MG132-induced moderate transla-
tional inhibition affected the NSs-induced PKR degradation in
MG132-treated cells. For example, if the NSs-induced PKR
downregulation requires an unstable host protein, then the
MG132-induced moderate translational suppression would pre-
vent accumulation of this putative host protein, resulting in
inhibition of the NSs-induced PKR downregulation. Obviously
further studies are required to elucidate the mechanism of PKR
downregulation mediated by RVFV NSs.
Materials and Methods
Cells and viruses
Vero E6 cells, wild-type mouse embryonic fibroblast (MEF) cells
and Pkr
0/0 MEF cells [37] were maintained in Dulbecco’s modified
minimum essential medium (DMEM) (Invitrogen) containing 10%
fetal bovine serum. BHK/T7-9 cells [63], which stably express T7
RNA polymerase, were grown in MEM-alpha (Invitrogen)
containing 10% fetal bovine serum (FBS). Penicillin (100 U/ml)
and streptomycin (100 mg/ml) (Invitrogen) were added to the
media. BHK/T7-9 cells were selected in medium containing
600 mg/ml hygromycin (Cellgro). An RVFV vaccine candidate
MP-12 [13] and recombinant MP-12 [19] were used for the
experiments, and infectivity was assessed by a plaque assay in Vero
E6 cells.
Drug treatment
Cells were treated with transcriptional inhibitors, ActD (Sigma)
(5 mg/ml) or a-amanitin (Sigma) (50 mg/ml) immediately after
infection or transfection. To induce the inhibition of proteasome
function, cells were immediately treated with MG132 (Sigma) at
10 mM or lactacystin (Sigma) at 50 mM after infection or
transfection. To suppress PKC activity, cells were treated with a
general PKC inhibitor, GO ¨ 6983 (Calbiochem) at 100 nM
immediately after infection with rMP12-rLuc or MP-12. Cells
were treated with puromycin (Cellgro) at 100 mg/ml immediately
after infection or transfection to inhibit cellular translation.
Plasmid constructions
Standard molecular biological techniques, including a PCR-
based mutagenesis method, were used for plasmid constructions.
PCR fragments encoding PKRDE7 ORF with an N-terminal
Flag-tag sequence were cloned between the Hpa I and Spe I sites of
pProT7-S(+) plasmid [19], designated as pProT7-S(+)-PKRDE7.
PCR fragments encoding the rLuc ORF or NSs with a C-terminal
Flag-tag sequence were cloned between the Hpa I and Spe I sites of
the pProT7-S(+) plasmid, designated as pProT7-S(+)-rLuc-Flag or
pProT7-S(+)-NSs-Flag, respectively. All of the constructs were
confirmed to have the expected sequences. The PCR product of
the entire human PKR ORF carrying a point mutation at K296R
and the N-terminal myc tag was cloned between KpnI and XhoIo f
pcDNA3.1myc-His (Invitrogen), resulted in pcDNA3.1-Myc-
PKR296R.
Virus rescue
A recombinant MP-12 carrying the PKRDE7 ORF, rLuc-Flag
or the NSs-Flag in the place of the NSs ORF was recovered as
described previously [19]. Briefly, subconfluent monolayers of
BHK/T7-9 cells were co-transfected with an S-genome RNA
expression plasmid, such as pProT7-S(+)-PKRDE7, pProT7-S(+)-
rLuc-Flag or pProT7-S(+)-NSs-Flag, and a mixture of pPro-T7-
M(+), pPro-T7-L(+), pT7-IRES-vN, pCAGGS-vG, and pT7-
IRES-vL using TransIT-LT1 (Mirus Bio Corporation). The
culture medium was replaced with fresh medium 24 h later. At
5 days post-transfection, the culture supernatants were collected,
clarified and then inoculated into VeroE6 cells. The supernatant
of infected VeroE6 cells at 3 days post-infection was used for the
experiment.
RNA transfection
RVFV MP-12 or ZH501 NSs ORF, or CAT ORF were cloned
downstream of the T7 promoter between the Kpn Ia n dXho I sites of
the pcDNA3.1-myc-HisA (Invitrogen) plasmid. For rLuc RNA
transcripts, the rLuc ORF in pRL-SV40 plasmid (Promega
Corporation)was inserted downstreamoftheT7 promoter.Capped
and polyadenylated RNA transcripts were synthesized in vitro by
using mMESSAGE mMACHINE T7 Ultra (Ambion) according to
the manufacturer’s instructions [64]. One microgram of in vitro-
synthesized RNA transcripts was transfected into 293 cells in a 12-
well plate with a TransIT-mRNA Transfection kit (Mirus Bio
Corporation) according to the manufacturer’s instructions.
Plaque assay
VeroE6 cells in 6-well plate were infected with a series of diluted
virus samples in 400 ml. After 1 h adsorption at 37uC, we removed
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(Difco Laboratories), 5% FBS and 5% tryptose phosphate broth.
The cells were incubated at 37uC for 3 days. Then, 2 ml of MEM
containing 0.6% agar, 100 mg of neutral red (N2889, Sigma), 5%
FBS and 5% tryptose phosphate broth were added into the wells,
and incubated for 16 h. The virus titers were determined in
triplicate.
Western blot analysis
Cells were lysed in sample buffer and boiled for 10 min. Equal
amounts of samples were subjected to sodium dodecyl sulfate-
polyacrylamide gel electrophoresis (SDS-PAGE). Proteins were
electroblotted onto polyvinylidene difluoride membranes (immo-
bilon P; Millipore). Western blot was performed as described
previously [27]. The following primary antibodies were used: anti-
RVFV [27]; anti-NSs [48]; anti-eIF2a (#9722, Cell Signaling
Tech.); anti–phospho-eIF2a (S51) (#9721, Cell Signaling Tech.);
anti-Flag M2 (F3165, Sigma); anti-PKR (#3072, Cell Signaling
Tech.); anti-Histone H1 (sc-8030, Santa Cruz Biotech.); anti–c-
Myc (sc-40, Santa Cruz Biotech.), and anti–b-actin (sc-1616, Santa
Cruz Biotech.).
IP-kinase assay
The IP-kinase assay was performed as described previously [65].
Briefly, 293 cells were mock-infected or infected with recombinant
MP-12 at an moi of 3. Cells were dissolved in lysis buffer
containing 10 mM Tris-HCl pH 7.6, 50 mM KCl, 2 mM
Magnesium acetate, 10 mM 2-mercaptoethanol, 1% Triton X-
100, 1 mM EDTA, phosphatase inhibitor cocktail (Sigma) and
proteasome inhibitor cocktail (Roche). After centrifugation at
10,0006g for 5 min, a cytoplasmic fraction was collected.
Cytoplasmic lysates were subjected to immunoprecipitation with
anti-PKR antibody (Santa Cruz Biotech, K-17). Protein A beads
that bound to the immunoprecipitated PKR were washed twice
with a buffer-A containing 20 mM Tris-HCl, pH 7.6; 50 mM
KCl; 400 mM NaCl; 5 mM 2-mercaptoethanol; 1% Triton X-
100; 1 mM EDTA; phosphatase inhibitor cocktail (Sigma);
proteasome inhibitor cocktail (Roche); and 20% glycerol. The
beads were further washed twice with buffer-B containing 20 mM
Tris-HCl, pH 7.6; 100 mM KCl; 5 mM 2-mercaptoethanol; 1%
Triton X-100; 0.1 mM EDTA; proteasome inhibitor cocktail
(Roche); and 20% glycerol. Then, washed beads were resuspended
in 26 kinase buffer containing 30 mM Hepes-KOH, pH 7.4;
2 mM dithiothreitol; 2 mM MgCl2; proteasome inhibitor cocktail
(Roche); and 10 mCi of [c-
32P] ATP (MP Biomedicals). The
suspension (20 ml) was incubated at 30uC for 20 min, and then 26
SDS sample buffer was added to terminate the reaction. The
samples were separated on 10% SDS-PAGE gel and visualized on
an autoradiograph. A portion of the samples were also used for
Western blot analysis by employing anti-PKR monoclonal
antibody (BD biosciences) to show the abundance of immunopre-
cipitated PKR.
Radiolabelling of proteins
For the radiolabelling of host and viral proteins in infected cells,
VeroE6 cells were incubated at 14.5 h post-infection for 30 min at
37uC with medium made up with MEM lacking methionine,
cystine, and L-glutamine (M2289, Sigma); 1% dialyzed FBS
(Invitrogen); 20 mM L-glutamine; penicillin (100 U/ml) and
streptomycin (100 mg/ml). Then, Trans[
35S]label metabolic
reagent (MP biomedicals) was directly added into the medium
(100 mCi/ml). After 1 h labelling, cells were washed with PBS
once and lysed in sample buffer. Equal amounts of samples were
subjected to SDS-PAGE in 10% polyacrylamide gel. The gel was
dried and exposed to X-ray film (KODAK BioMax XAR)
overnight at 280uC. For the radiolabelling of PKR, 293 cells
were mock-treated or transfected with pcDNA3.1-Myc-
PKRK296R, and labelled with Trans[
35S]label metabolic reagent
between 14 and 16 h post–DNA transfection. In some samples,
cell extracts were prepared with chase using a lysis buffer. In other
samples, cells were transfected with in vitro-synthesized RNA
transcripts encoding rLuc or MP-12 NSs. Then, cells were washed,
and incubated for 8 h in the presence of 2 mM methionine/
cysteine. At 8 h post–RNA transfection, cell extracts prepared
using lysis buffer, were employed for immunoprecipitation with
anti-Myc antibody (Santa Cruz: sc-40), as described in an IP-
kinase assay. Immunoprecipitated samples were separated on a
7.5% poryacrylamide gel and visualized on an autoradiograph.
dsRNA-binding assay
293 cells were mock-infected or infected with rMP12-rLuc-Flag,
rMP12-NSs-Flag or rMP12-PKRDE7 at an moi of 3. Alternative-
ly, 293 cells were transfected with in vitro-synthesized RNA
transcripts encoding MP-12 NSs. The cytoplasmic lysate was
harvested at 16 h.p.i. or 16 h post-transfection, and incubated
with poly C beads or poly I:C beads on ice for 45 minutes. After
washing beads with buffer-A for 4 times, the beads were mixed
with 26 sample buffer, and bound proteins were analyzed with
anti-Flag antibody (Sigma) on a Western blot.
Renilla luciferase assay
The luciferase assay was performed on a Renilla Luciferase Assay
System (E2810, Promega Corporation) according to the manu-
facturer’s instructions.
Northern blot analysis
Total RNA was harvested by Trizol reagent (Invitrogen), and
Northern blot was performed as described previously [27,64].
Briefly, total RNA was denatured and separated on 1.2%
denaturing agarose-formaldehyde gels and transferred onto a
nylon membrane (Nylon Membrane, positively charged, Roche).
Northern blot analysis was performed by using strand-specific
RNA probes for detecting IFN-b mRNA [64], GAPDH mRNA
[64], rLuc mRNA [27] or RVFV antiviral-sense S-segment / N-
mRNA [48].
Real-time PCR
293 cells in 6-well plates were transfected with 2 mg of in vitro-
synthesized RNA transcripts encoding rLuc or MP-12 NSs by
TransIT mRNA transfection kit (Mirus). Cells were mock-treated
or treated with ActD (5 mg/ml) immediately after RNA transfec-
tion. Total RNA were extracted by using an RNeasy Mini kit
(Qiagen) at 16 h post-transfection. For each sample, we used
500 ng of RNA to synthesize 1
st strand cDNA by High-Capacity
cDNA Reverse Transcription Kits (Applied Biosystems). Real-
Time PCR was performed at the Real-Time PCR core facility,
Sealy Center for Cancer Cell Biology, UTMB. We used an
Applied Biosystems made-to-order 206assay mix of primers and
TaqMan MGB probes (FAM dye-labled) for our target gene PKR
(Applied Biosystems: assay ID#: Hs01091592_m1) and pre-
developed an 18S rRNA (FAM-dye labelled probe) TaqMan
assay reagent (Applied Biosystems: 4352930E) for endogenous
control. Separate tubes (singleplex) real-time PCR was performed
with 40 ng cDNA for both target gene and endogenous control by
using a Taqman Gene expression master mix (Applied Biosystems:
4370074). The cycling parameters for real-time PCR were: UNG
activation at 50uC for 2 min, AmpliTaq activation at 95uC for
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at 60uC for 1 min (repeat 40 times) on ABI7000. Duplicate CT
values were analyzed by the comparative CT (DD CT) method, as
described by the manufacturer (Applied Biosystems). The amount
of target (2
2DDCT) was obtained by normalized to endogenous
reference (18S rRNA) and relative to a calibrator (one of the
experimental samples).
Supporting Information
Figure S1 Effects of ActD treatment on host translation
activities. (A) 293 cells cultured in 10-cm dishes were treated with
5 mg/ml of ActD (ActD) or were left untreated (Mock). Cells were
harvested at 16 h post-ActD-treatment in 900 ml of Lysis buffer
(50 mM Tris-HCl, pH 7.5; 5 mM MgCl2; 100 mM KCl; 1%
Triton X-100; 100 mg/ml cycloheximide; and 0.5 mg/ml heparin)
on ice for 5 min. The cytoplasmic lysates were collected after the
removal of nucleus by centrifugation at 10,0006g for 5 min. The
lysates were loaded onto a 10–50% linear sucrose gradient
containing 50 mM Tris-HCl, pH 7.5; 5 mM MgCl2; 100 mM
KCl; 0.5 mM dithiothreitol; 100 mg/ml cycloheximide; and
0.5 mg/ml heparin, and centrifuged at 38,000 rpm for 3 h at
4uC using a Beckman SW41 rotor. The gradients were pumped by
syringe pump (Brandel) and analyzed by a density gradient
fractionator (Brandel) connected to an ISCO UA-6 (ISCO Inc.) at
the absorbance of 254 nm according to the manufacturer’s
instructions. The data were representative of two independent
experiments. (B) 293 cells were transfected with in vitro-
synthesized rLuc RNA transcripts and mock-treated (no drug) or
immediately treated with 5 mg/ml of ActD (ActD) or 50 mg/ml of
a-amanitin (Amanitin). Luciferase activities were measured at 16 h
post-transfection. The data shown in the graphs (mean+/
2standard deviation) were obtained from three independent
experiments with p values by using Student’s t-test (*: p,0.05).
Found at: doi:10.1371/journal.ppat.1000287.s001 (4.02 MB TIF)
Figure S2 Effects of different concentrations of ActD or a-
amanitin on eIF2a phosphorylation and N protein accumulation
in rMP-12-infected cells. VeroE6 cells were infected with rMP12-
rLuc at an moi of 3, and then treated with different concentrations
of ActD or a-amanitin. Cell extracts and culture supernatants were
harvested at 16 h.p.i. Note that ActD suppresses about 80% of
RNA polymerase I activity at 0.04 mg/ml, and about 80% of RNA
polymerase II and III at 4.0 mg/ml [28], while a-amanitin
suppresses nearly 100% of RNA polymerase II and about 50%
of RNA polymerase III at 50 mg/ml [64]. (A) Western blot analysis
of N protein, phosphorylated eIF2a, total eIF2a and a-actin in
each cell extract. (B) Top panels represent the relative abundance
of phosphorylated eIF2a and total eIF2a. The relative abundance
of phosphorylated eIF2a and total eIF2a in the untreated cells
represents 100%. The middle panels and the bottom panels
represent the abundance of N protein and the virus titers,
respectively. The results were obtained from three independent
experiments with p values by using Student’s t-test (*: p,0.05).
Found at: doi:10.1371/journal.ppat.1000287.s002 (4.33 MB TIF)
Figure S3 Effects of pan-caspase inhibitor Z-VADfmk on PKR-
mediated eIF2a phosphorylation in infected cells. VeroE6 cells
were mock-infected (Mock) infected with rMP12-rLuc (rMP12-
rLuc) and then treated with 5 mg/ml ActD (Act) or 50 mg/ml of a-
amanitin (Ama) or mock-treated (M) in the presence or absence of
100 mM of Z-VADfmk. Cells and culture supernatants were
harvested at 16 h.p.i. (A) Western blot analysis of eIF2a,
phosphorylated eIF2a, cleaved caspase 3 using anti-Cleaved
Caspase 3, Asp175, antibody (Cell Signaling Tech. #9661), and
a-actin in the absence (Top) and presence (Bottom) of Z-VADfmk.
The data are representative of three independent experiments. (B)
The relative abundance of phosphorylated eIF2a and total eIF2a.
The relative abundance of phosphorylated eIF2a and total eIF2a
in the mock-infected, mock-treated cells represents 100%. The
average and standard deviation from three independent experi-
ments were shown (*: p,0.05 compared to mock-treated cells). (C)
Virus titers of rMP12-rLuc from three independent experiments
were shown (*: p,0.05 compared to mock-treated cells).
Found at: doi:10.1371/journal.ppat.1000287.s003 (2.29 MB TIF)
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